Cargando…
Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure
Philadelphia‐negative (Ph(−)) myeloproliferative neoplasms (MPN) do rarely transform to acute lymphoblastic leukemia (ALL). While causality is difficult to establish, a few cases of ALL arising after exposure to lenalidomide for registered indications (multiple myeloma, myelodysplastic syndrome with...
Autores principales: | Alhuraiji, Ahmad, Naqvi, Kiran, Huh, Yang O., Ho, Coty, Verstovsek, Srdan, Bose, Prithviraj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771935/ https://www.ncbi.nlm.nih.gov/pubmed/29375856 http://dx.doi.org/10.1002/ccr3.1264 |
Ejemplares similares
-
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020) -
Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
por: Fiskus, Warren, et al.
Publicado: (2022) -
Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017) -
Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019) -
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)